![Barbara Yanni](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Barbara Yanni
Directeur/Membre du Conseil chez
TREVENA, INC.
Fortune : 218 281 $ au 31/07/2026
Profil
Barbara Yanni is currently Non-Executive Director at Pharming Group NV since 2020, Independent Director at Trevena, Inc. since 2014, and Independent Director at Mesentech, Inc. since 2020.
Former roles include Director at Symic Bio, Inc. and Symic Holdings LLC from 2015 to 2019, Independent Director at ABIONYX Pharma SA from 2018 to 2020, Independent Director at Akcea Therapeutics, Inc. from 2019 to 2020, Independent Director at Oncorus, Inc. from 2021 to 2023, Independent Director at Vaccinex, Inc., and Chief Licensing Officer & Vice President at Merck & Co., Inc. from 2001 to 2014.
Education includes graduate studies at New York University and Stanford Law School, and undergraduate studies at Wellesley College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
PHARMING GROUP NV 0,03 % | 28/05/2026 | 216 032 ( 0,03 % ) | 218 281 $ | 31/07/2026 |
Postes actifs de Barbara Yanni
| Sociétés | Poste | Début |
|---|---|---|
| TREVENA, INC. | Directeur/Membre du Conseil | 01/07/2014 |
| PHARMING GROUP N.V. | Directeur/Membre du Conseil | 11/12/2020 |
Mesentech, Inc.
 Mesentech, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drug conjugates | Directeur/Membre du Conseil | 01/11/2020 |
Anciens postes connus de Barbara Yanni
| Sociétés | Poste | Fin |
|---|---|---|
| ONCORUS, INC. | Directeur/Membre du Conseil | 27/07/2023 |
| AKCEA THERAPEUTICS, INC. | Directeur/Membre du Conseil | 12/10/2020 |
| ABIONYX PHARMA SA | Directeur/Membre du Conseil | 01/01/2020 |
Symic Bio, Inc.
 Symic Bio, Inc. BiotechnologyHealth Technology Develops new category of therapeutics | Directeur/Membre du Conseil | 01/08/2019 |
Symic Holdings LLC
 Symic Holdings LLC BiotechnologyHealth Technology Develops new category of therapeutics | Directeur/Membre du Conseil | 01/01/2019 |
Formation de Barbara Yanni
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
90
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Vaccinex, Inc.
 Vaccinex, Inc. BiotechnologyHealth Technology Discovers and develops targeted biotherapeutics | Health Technology |
Symic Bio, Inc.
Symic Bio, Inc. BiotechnologyHealth Technology Develops new category of therapeutics | Health Technology |
Symic Holdings LLC
Symic Holdings LLC BiotechnologyHealth Technology Develops new category of therapeutics | Health Technology |
Pharming Group NV
 Pharming Group NV Pharmaceuticals: MajorHealth Technology Develops and commercializes protein replacement therapies and precision medicines | Health Technology |
New York University
 New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Wellesley College
 Wellesley College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
ABIONYX Pharma SA
 ABIONYX Pharma SA Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes novel HDL therapies for the treatment of cardiovascular and metabolic diseases | Health Technology |
Trevena, Inc.
 Trevena, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company focused on the development and commercialization of novel medicines for patients affected by central nervous system | Health Technology |
Stanford Law School
 Stanford Law School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Akcea Therapeutics, Inc.
 Akcea Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops drugs for cardiometabolic lipid disorders | Health Technology |
Oncorus, Inc.
 Oncorus, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops next generation immunotherapy platform to treat cancer | Health Technology |
Mesentech, Inc.
Mesentech, Inc. Pharmaceuticals: MajorHealth Technology Develops novel drug conjugates | Health Technology |
